Novartis is the latest pharmaceutical company to throw some wikinomics at its approach to research and development. After investing millions of dollars trying to unlock the genetic basis of type 2 diabetes, the company released all of its raw data on the Internet, for free. To some, this will sound peculiar. After all, type 2 diabetes and related cardiovascular risk factors — including obesity, high blood pressure, and high cholesterol — are among the most [...]
2 Comments

Read More